Celsion CorporationCLSN announced data from a preclinical study on its immunotherapy candidate, GEN 1 IL 12, in combination with Avastin and Doxil for the treatment of ovarian cancer. GEN 1 is Celsion’s DNA based immunotherapy. The company conducted the